Home›Pazopanib

Pazopanib

Kinase InhibitorProtein Kinase InhibitorsCytochrome P450 3A4 Inhibitors

Route: Oral

10 interactions on record⛔ Black Box Warning

Pazopanib has 10 known drug interactions based on U.S. FDA drug labeling data. 7 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Androgen-Deprivation Therapeutic Drugs, Cyp3a Inducers, Itraconazole. Patients taking Pazopanib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 10
Major: 7
Moderate: 1

Major (7)

Pazopanib + Androgen-Deprivation Therapeutic Drugs— Coadministration may inhibit metabolism and cause serious adverse reactions. Not recommended.
Pazopanib + Cyp3a Inducers— Coadministration may decrease pazopanib plasma concentrations. Pazopanib not recommended with chronic use of strong CYP3…
Pazopanib + Itraconazole— Axitinib Bosutinib Cabazitaxel Cabozantinib Ceritinib Cobimetinib Crizotinib Dabrafenib Dasatinib Docetaxel Ibrutinib La…
Pazopanib + Mao Inhibitors— Coadministration increases pazopanib concentrations. Avoid coadministration; if unavoidable, reduce pazopanib dose.
Pazopanib + P-Gp Or Bcrp Substrates— Coadministration may increase pazopanib concentrations. Avoid concomitant use.
Pazopanib + Pazopanib Hydrochloride— 7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Avoid coadministration of pazopanib tablets with strong CYP3A4 inhibitors.…
Pazopanib + Simvastatin— Concomitant use increases risk of alanine aminotransferase (ALT) elevations. Requires weekly monitoring of liver functio…

Moderate (1)

Pazopanib + Anakinra— Avoid concomitant use with pazopanib. Consider short-acting antacids instead.

Pazopanib + Androgen-Deprivation Therapeutic Drugs⚠️Major

Coadministration may inhibit metabolism and cause serious adverse reactions. Not recommended.

Pazopanib + Cyp3a Inducers⚠️Major

Coadministration may decrease pazopanib plasma concentrations. Pazopanib not recommended with chronic use of strong CYP3A4 inducers.

Pazopanib + Itraconazole⚠️Major

Axitinib Bosutinib Cabazitaxel Cabozantinib Ceritinib Cobimetinib Crizotinib Dabrafenib Dasatinib Docetaxel Ibrutinib Lapatinib Nilotinib Olaparib Pazopanib Sunitinib Trabectedin Trastuzumab-emtansine Vinca alkaloids Avoid use during and 2 weeks after itraconazole treatment.

Pazopanib + Mao Inhibitors⚠️Major

Coadministration increases pazopanib concentrations. Avoid coadministration; if unavoidable, reduce pazopanib dose.

Pazopanib + P-Gp Or Bcrp Substrates⚠️Major

Coadministration may increase pazopanib concentrations. Avoid concomitant use.

Pazopanib + Pazopanib Hydrochloride⚠️Major

7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Avoid coadministration of pazopanib tablets with strong CYP3A4 inhibitors. If coadministration cannot be avoided, reduce the dose of pazopanib tablets. Pazopanib tablets are not recommended if chronic use of strong CYP3A4 inducers cannot be avoided.

Pazopanib + Simvastatin⚠️Major

Concomitant use increases risk of alanine aminotransferase (ALT) elevations. Requires weekly monitoring of liver function and may require dose reduction or discontinuation based on hepatotoxicity severity.

Pazopanib + Anakinra🟡Moderate

Avoid concomitant use with pazopanib. Consider short-acting antacids instead.

Pazopanib + Esomeprazoleℹ️Unknown

7.4 Concomitant Use With Gastric Acid-Reducing Agents Concomitant use of pazopanib tablets with esomeprazole, a PPI, decreased the exposure of pazopanib.

Pazopanib + Lomitapide Mesylateℹ️Unknown

7.2 Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology (12.3) ] .

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.